Pharmaceutical group · Canada
Apotex
A group of 18 companies with 1,669 medicines in 6 countries.
Group structure
18 companies in 6 countries
Loading your page…
Loading your page…
Pharmaceutical group · Canada
A group of 18 companies with 1,669 medicines in 6 countries.
18 companies in 6 countries
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Every medicine of every company in the group, current ones first.
1–25 of 1,669
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| 24HR NASAL ALLERGY RELIEF50 mcg / act · Spray (Metered-Dose) | Fluticasone | Canada | Marketed | 2017 |
| ACETAMINOPHEN CAPLETS 325 MG325 mg · Tablet | Paracetamol | Canada | Marketed | 2011 |
| ACETAMINOPHEN CAPLETS 500 MG500 mg · Tablet | Paracetamol | Canada | Marketed | 2011 |
| ACETAMINOPHEN/DEXTROMETHORPHAN/PSEUDOEPHEDRINE325 mg + 15 mg + 30 mg · Capsule | Paracetamol, Dextromethorphan, Pseudoephedrine | Canada | Authorised | |
| ACETAMINOPHEN EASY SWALLOW500.0 mg · Tablet | Paracetamol | Canada | Authorised | |
| ACETAMINOPHEN HEADACHE ULTRA RELIEF500 mg + 65 mg · Tablet | Paracetamol, Caffeine | Canada | Not marketed | 2008 |
| ACETAMINOPHEN LIQUID GEL CAPSULES325 mg · Capsule | Paracetamol | Canada | Not marketed | 2017 |
| ACETAMINOPHEN/PSEUDOEPHEDRINE/DEXTROMETHORPHAN/DOXYLAMINE325 mg + 15 mg + 6.25 mg + 30 mg · Capsule | Paracetamol, Dextromethorphan, Doxylamine, Pseudoephedrine | Canada | Authorised | |
| ACETAMINOPHEN TABLETS USP 325 MG325 mg · Tablet | Paracetamol | Canada | Marketed | 2011 |
| ACETAMINOPHEN TABLETS USP 500 MG500 mg · Tablet | Paracetamol | Canada | Marketed | 2011 |
| ACID CONTROL10 mg · Tablet | Famotidine | Canada | Not marketed | 2000 |
| ACID CONTROL20 mg · Tablet | Famotidine | Canada | Not marketed | 2014 |
| ACID REDUCER150 mg · Tablet | Ranitidine | Canada | Not marketed | 2014 |
| ACID REDUCER75 mg · Tablet | Ranitidine | Canada | Not marketed | 1999 |
| ACYCLOVIR200 mg · Tablet | Aciclovir | Canada | Authorised | 1996 |
| ACYCLOVIR800 mg · Tablet | Aciclovir | Canada | Authorised | 1996 |
| ACYCLOVIR400 mg · Tablet | Aciclovir | Canada | Authorised | 1996 |
| AFLIVU2 mg / 0.05 ml · Solution | Aflibercept | Canada | Marketed | 2025 |
| AFLIVU2 mg / 0.05 ml · Solution | Aflibercept | Canada | Marketed | 2025 |
| ALENDRONATE SODIUM10mg base | 35mg base | 40mg base | 5mg base | 70mg base · Tablet | Alendronic acid | United States | Marketed | 2008 |
| ALFUZOSIN HYDROCHLORIDE10mg · Tablet, extended release | Alfuzosin | United States | Marketed | 2011 |
| ALKERAN2MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · Tablet | Melphalan | United States | Not marketed | 1964 |
| ALKERAN50MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · Injectable | Melphalan | United States | Not marketed | 1992 |
| ALLER-RELIEF10 mg · Tablet | Cetirizine | Canada | Not marketed | 1999 |
| ALLERGY LIQUID GEL CAPSULES25 mg · Capsule | Diphenhydramine | Canada | Not marketed | 2016 |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| Canada | 1,382 | 1,207 | 175 | CompaniesAll medicines |
| Spain | 90 | 0 | 90 | CompaniesAll medicines |
| Saudi Arabia | 75 | 75 | 0 | CompaniesAll medicines |
| Brazil | 62 | 0 | 62 | CompaniesAll medicines |
| United States | 58 | 51 | 7 | CompaniesAll medicines |
| European Union (EMA) | 2 | 0 | 2 | CompaniesAll medicines |
Also in the registers of Singapore
The ATC groups most of its medicines belong to, largest first.
The active substances in most of its medicines.
How the registers spell it, normalised: legal forms, accents and capitals removed.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Companies are grouped by Prognia from the names regulators publish; not an official corporate structure.
Source: European Medicines Agency (EPAR data).
Licence: EMA reuse policy (source acknowledgement required)
Fuente de la información: AEMPS (CIMA).
Licence: AEMPS open data reuse with attribution
Source: U.S. FDA, Drugs@FDA / openFDA. FDA does not endorse this site.
Licence: Public domain (U.S. Government work)
Anvisa published factual open-data CSV https://dados.anvisa.gov.br/dados/CONSULTAS/PRODUTOS/TA_CONSULTA_MEDICAMENTOS.CSV, HTTP version Mon, 12 Oct 2026 11:45:25 GMT; acquired 12 October 2026; original source states and timestamps retained.
Licence: Brazil federal factual open data, consolidated Decreto 8777/2016 article 4; attribution and third-party exceptions
Anvisa, official medicine/API manufacturer factual export, HTTP source version Fri, 09 Oct 2026 08:21:54 GMT, acquired 2026-10-09; exact unmodified native identifiers and fields preserved.
Licence: Brazil federal factual open-data reuse; Decreto 8777/2016 consolidated article 4 and third-party exceptions
Health Canada, Drug Product Database, company API, entire response observed 2026-10-10T15:12:05.508784+00:00; native facts projected by Prognia.
Licence: Open Government Licence Canada
Health Canada, Drug Product Database, drugproduct API, entire response observed 2026-10-10T15:12:07.336870+00:00; native facts projected by Prognia.
Licence: Open Government Licence Canada
Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA presentaciones, acquired 11 October 2026 UTC; each source response/update date retained.
Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required
Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA medicamentos, acquired 11 October 2026 UTC; each source response/update date retained.
Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required
Saudi Food and Drug Authority (SFDA), foreign human medicine open-data listing, source scope 2023, retrieved 11 October 2026 UTC; exact original file and response modification date retained.
Licence: Exact SFDA open-data section explicitly offers freely usable named human medicine workbooks; factual-data scope only
Contains information from HSA Listing of Registered Therapeutic Products accessed on 8 October 2026 from data.gov.sg, under Singapore Open Data Licence 1.0: https://data.gov.sg/open-data-licence
Licence: Singapore Open Data Licence
Report an error or request removalCorrections from the company itself are welcome.
Ranked by their number of medicines.